Because PLD1 and PLD2 deficiency is relatively well tolerated in mammals taken together, these findings further support the concept that targeting PLD1 and PLD2 or their downstream signaling targets may be an effective therapeutic approach in settings such as cardiovascular disease and cancer where PLD activity is elevated or aberrantly regulated. Here, GPLD1 is linked to cancer.